IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE FOR RELAPSED MULTIPLE MYELOMA: AN EARLY SINGLE CENTER EXPERIENCE IN RUSSIA

被引：0
|
作者：
Luchinin, A. [1 ]
Semochkin, S. [2 ]
Minaeva, N. [1 ]
Samarina, S. [1 ]
机构：
[1] Med Biol Agcy, Kirov Sci Res Inst Hematol & Blood Transfus, Kirov, Russia
[2] Pirogov Russian Natl Res Med Univ, Moscow, Russia
来源：
HAEMATOLOGICA | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P59
引用
收藏
页码：40 / 40
页数：1
相关论文
共 50 条
  • [31] Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study
    M. Macro
    C. Hulin
    L. Vincent
    A. Charvet-Rumpler
    L. Benboubker
    C. Calmettes
    A.-M. Stoppa
    K. Laribi
    L. Clement-Filliatre
    H. Zerazhi
    F. Honeyman
    V. Richez
    F. Maloisel
    L. Karlin
    J. Barrak
    C. Chouaid
    X. Leleu
    [J]. Annals of Hematology, 2023, 102 : 2137 - 2151
  • [32] Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study
    Macro, M.
    Hulin, C.
    Vincent, L.
    Charvet-Rumpler, A.
    Benboubker, L.
    Calmettes, C.
    Stoppa, A. -m.
    Laribi, K.
    Clement-Filliatre, L.
    Zerazhi, H.
    Honeyman, F.
    Richez, V.
    Maloisel, F.
    Karlin, L.
    Barrak, J.
    Chouaid, C.
    Leleu, X.
    [J]. ANNALS OF HEMATOLOGY, 2023, 102 (08) : 2137 - 2151
  • [33] Ixazomib, lenalidomide, and dexamethasone combination in “real-world” clinical practice in patients with relapsed/refractory multiple myeloma
    Juraj Sokol
    Tomas Guman
    Juraj Chudej
    Monika Hlebaskova
    Natalia Stecova
    Lubica Valekova
    Monika Kucerikova
    Jan Stasko
    [J]. Annals of Hematology, 2022, 101 : 81 - 89
  • [34] Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma
    Michael Slade
    Thomas G. Martin
    Nitya Nathwani
    Mark A. Fiala
    Michael P. Rettig
    Feng Gao
    Abhinav Deol
    Francis K. Buadi
    Jonathan L. Kaufman
    Craig C. Hofmeister
    Tara K. Gregory
    Jesus Berdeja
    Ajai Chari
    Ashley Rosko
    Ravi Vij
    [J]. Leukemia, 2022, 36 : 2917 - 2921
  • [35] Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma
    Slade, Michael
    Martin, Thomas G.
    Nathwani, Nitya
    Fiala, Mark A.
    Rettig, Michael P.
    Gao, Feng
    Deol, Abhinav
    Buadi, Francis K.
    Kaufman, Jonathan L.
    Hofmeister, Craig C.
    Gregory, Tara K.
    Berdeja, Jesus
    Chari, Ajai
    Rosko, Ashley
    Vij, Ravi
    [J]. LEUKEMIA, 2022, 36 (12) : 2917 - 2921
  • [36] CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SINGLE CENTRE REAL-LIFE EXPERIENCE
    Guidotti, F.
    Ferla, V
    Gregorini, A., I
    Rossi, F. G.
    Pompa, A.
    [J]. HAEMATOLOGICA, 2018, 103 : 38 - 38
  • [37] Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center Real Life Experience
    Canto, Chiara
    Ranucci, Elena
    Pulini, Stefano
    Santoleri, Fiorenzo
    Morelli, Anna Maria
    Fioritoni, Francesca
    Falorio, Simona
    Torti, Lorenza
    Spadano, Antonio
    D'Aloisio, Marianna
    Di Ianni, Mauro
    Santarone, Stella
    Di Bartolomeo, Paolo
    [J]. BLOOD, 2018, 132
  • [38] Efficacy and safety of carfilzomib, lenalidomide, and dexamethasone versus ixazomib, lenalidomide, and dexamethasone in real world patients with relapsed/refractory multiple myeloma: KMM2004 study
    Kim, Do Young
    Shin, Ho-Jin
    Min, Chang-Ki
    Eom, Hyeon-Seok
    Jung, Jongheon
    Kim, Kihyun
    Lee, Jae Hoon
    Yoo, Kwai Han
    Lee, Ji Yun
    Byun, Ja Min
    Kim, Sung-Hyun
    Lee, Ji Hyun
    Cho, Hee Jeong
    Lee, Sang Min
    Do, Young Rok
    Park, Sungwoo
    Lee, Junglim
    Lee, Seung-Shin
    Kang, Hye Jin
    Park, Young Hoon
    Lim, Sung-Nam
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S189 - S190
  • [39] Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma
    Buadi, Francis K.
    Lacy, Martha Q.
    Laplant, Betsy
    Wolfe, Eric
    Gertz, Morie A.
    Ailawadhi, Sikander
    Hayman, Suzanne R.
    Go, Ronald S.
    Helgeson, Dania Kaehlyn
    Roy, Vivek
    Reeder, Craig B.
    Fonder, Amie
    Hwa, Yi L.
    Hobbs, Miriam A.
    Bergsagel, P. Leif
    Fonseca, Rafael
    Dingli, David
    Gonsalves, Wilson I.
    Kapoor, Prashant
    Chanan-Khan, Asher A.
    Kourelis, Taxiarchis
    Larsen, Jeremy
    Russell, Stephen J.
    Lust, John A.
    Sher, Taimur
    Siddiqui, Mustaqeem A.
    Stewart, A. Keith
    Warsame, Rahma M.
    Rajkumar, S. Vincent
    Kyle, Robert A.
    Kumar, Shaji K.
    [J]. BLOOD, 2019, 134
  • [40] Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma
    Richter, Joshua R.
    Bilotti, Elizabeth
    McBride, Laura
    Schmidt, Linda
    Gao, Zhijie
    Tufail, Madiha
    Anand, Palka
    McNeill, Ann
    Bednarz, Urszula
    Graef, Thorsten
    Vesole, David H.
    Siegel, David S.
    [J]. BLOOD, 2011, 118 (21) : 1706 - 1706
12345